Migalastat
Clinical data | |
---|---|
Pronunciation | mi GAL a stat |
Trade names | Galafold |
Other names | DDIG, AT1001, 1-deoxygalactonojirimycin |
AHFS/Drugs.com | Monograph |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 75% |
Protein binding | None |
Metabolites | O-glucuronides (<15%) |
Elimination half-life | 3–5 hours (single dose) |
Excretion | Urine (77%), feces (20%) |
Identifiers | |
| |
JSmol) | |
| |
|
Migalastat, sold under the brand name Galafold, is a medication for the treatment of Fabry disease, a rare genetic disorder. It was developed by Amicus Therapeutics. The US Food and Drug Administration (FDA) granted it orphan drug status in 2004,[5] and the European Commission followed in 2006.[6] The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) granted the drug a marketing approval under the name Galafold in May 2016.[7][8][9]
The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.[10]
Medical uses
Migalastat is used for the long-term treatment of Fabry disease in adults and adolescents aged 16 or older with an amenable mutation of the enzyme
Based on an in vitro test, Amicus Therapeutics has published a list of 269 amenable and nearly 600 non-amenable mutations. About 35 to 50% of people with Fabry have an amenable mutation.[8]
Adverse effects
The most common side effect in
Interactions
When combined with
Migalastat does not inhibit or induce
Pharmacology
Mechanism of action
Fabry disease is a genetic disorder caused by various mutations of the enzyme α-GalA, which is responsible for breaking down the sphingolipid globotriaosylceramide (Gb3), among other glycolipids and glycoproteins. Some of these mutations result in misfolding of α-GalA, which subsequently fails protein quality control in the endoplasmic reticulum and is decomposed. Lack of functional α-GalA leads to accumulation of Gb3 in blood vessels and other tissues, with a wide range of symptoms including kidney, heart, and skin problems.[11]
Migalastat is a potent, orally available
When the enzyme reaches its destination, the
-
The enzymealpha-galactosidaseA (α-GalA)
-
Migalastat ("top" view)
Pharmacokinetics
Migalastat is almost completely absorbed from the gut; taking the drug together with food decreases its absorption by about 40%. Total
Only a small fraction of a migalastat dose is metabolized, mainly to three
Chemistry
Migalastat is used in form of the
The structure is formally derived from nojirimycin.[citation needed]
History
Migalastat was isolated as a fermentation product of the bacterium Streptomyces lydicus (strain PA-5726) in 1988 and called 1-deoxygalactonojirimycin.[15][16] In 2004, it was designated orphan drug status by the US FDA for the treatment of Fabry disease,[5] and in 2006 the European CHMP did likewise.[17] The sponsorship for the drug was transferred several times over the following years: from Amicus Therapeutics to
Two phase III clinical trials with a total of about 110 subjects were conducted between 2009 and 2015, one
In September 2015, Amicus announced that it would submit a
See also
- Miglustat, a drug for the treatment of Gaucher disease, with a similar structure
- 1-Deoxynojirimycin, a stereoisomer of migalastat
References
- ^ "Galafold (Amicus Therapeutics Pty Ltd)". tga.gov.au. Retrieved 29 March 2023.
- ^ "Prescription medicines: registration of new chemical entities in Australia, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 9 April 2023.
- ^ "Prescription medicines and biologicals: TGA annual summary 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 31 March 2024.
- ^ "Genetic disorders". Health Canada. 9 May 2018. Retrieved 13 April 2024.
- ^ a b "Migalastat Orphan Drug Designations and Approvals". U.S. Food and Drug Administration (FDA). Retrieved 16 September 2020.
- ^ "EU/3/06/368". European Medicines Agency (EMA). 17 September 2018. Retrieved 16 September 2020.
- ^ a b c "Amicus Therapeutics Announces European Commission Approval for Galafold (Migalastat) in Patients with Fabry Disease in European Union". GlobeNewswire. 31 May 2016.
- ^ a b c d e f g h i j "Summary of Product Characteristics for Galafold" (PDF). European Medicines Agency. June 2016.
- ^ "Galafold EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 16 September 2020.
- ^ New Drug Therapy Approvals 2018 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2019. Retrieved 16 September 2020.
- ^ PMID 27043200.
- S2CID 12629461.
- PMID 26252393.
- ^ "Assessment report EMA/272226/2016" (PDF). EMA. 1 April 2016.
- ^ ISBN 978-0-470-03391-3.
- .
- ^ "Galafold". European Medicines Agency. 1 April 2016.
- ^ "Public summary of opinion on orphan designation". European Medicines Agency. 29 April 2014.
- ^ "Amicus Therapeutics Plans to Submit NDA for Migalastat for Fabry Disease Following Positive Pre-NDA Meeting With FDA". Drugs.com. 15 September 2015.
- ^ Adams B (November 29, 2016). "FDA rejects quick Amicus Fabry drug read-through, new data not expected till 2019". FierceBiotech.
- ^ Carroll J (February 12, 2018). "Once rejected, FDA now rolls out a short red carpet for Amicus' migalastat". Endpoints.